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Background: Embryonal Rhabdomyosarcoma (RMS) is a pediatric soft-tissue sarcoma derived from myogenic
precursors that is characterized by a good prognosis in patients with localized disease. Conversely, metastatic
tumors often relapse, leading to a dismal outcome. The histone methyltransferase EZH2 epigenetically suppresses
skeletal muscle differentiation by repressing the transcription of myogenic genes. Moreover, de-regulated EZH2
expression has been extensively implied in human cancers. We have previously shown that EZH2 is aberrantly
over-expressed in RMS primary tumors and cell lines. Moreover, it has been recently reported that EZH2 silencing in
RD cells, a recurrence-derived embryonal RMS cell line, favors myofiber-like structures formation in a pro-differentiation
context. Here we evaluate whether similar effects can be obtained also in the presence of growth factor-supplemented
medium (GM), that mimics a pro-proliferative microenvironment, and by pharmacological targeting of EZH2 in RD cells
and in RD tumor xenografts.
Methods: Embryonal RMS RD cells were cultured in GM and silenced for EZH2 or treated with either the
S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep) that induces EZH2 degradation, or
with a new class of catalytic EZH2 inhibitors, MC1948 and MC1945, which block the catalytic activity of EZH2. RD cell
proliferation and myogenic differentiation were evaluated both in vitro and in vivo.
Results: Here we show that EZH2 protein was abnormally expressed in 19 out of 19 (100%) embryonal RMS primary
tumors and cell lines compared to their normal counterparts. Genetic down-regulation of EZH2 by silencing in GM
condition reduced RD cell proliferation up-regulating p21Cip1. It also resulted in myogenic-like differentiation testified
by the up-regulation of myogenic markers Myogenin, MCK and MHC. These effects were reverted by enforced
over-expression of a murine Ezh2, highlighting an EZH2-specific effect. Pharmacological inhibition of EZH2 using either
DZNep or MC inhibitors phenocopied the genetic knockdown of EZH2 preventing cell proliferation and restoring
myogenic differentiation both in vitro and in vivo.
Conclusions: These results provide evidence that EZH2 function can be counteracted by pharmacological inhibition in
embryonal RMS blocking proliferation even in a pro-proliferative context. They also suggest that this approach could
be exploited as a differentiation therapy in adjuvant therapeutic intervention for embryonal RMS.
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Pediatric rhabdomyosarcoma (RMS) is a locally invasive
soft-tissue sarcoma with a predisposition to metastasize
that accounts for ~ 30% of all soft-tissue sarcomas (STS)
and for 7-8% of all solid tumors in childhood [1]. Embry-
onal RMS is the major histopathologic subtype, accounting
for 60% of all RMS cases and, when nonmetastatic, shows
a 5-year overall survival of 70% [2]. Childhood cancer sta-
tistics show that the outcome for young patients with RMS
has tremendously improved from 53% in 1975–1978 to
68% in 1979–1982 [3], but unfortunately current treat-
ments for embryonal RMS in the metastatic form often do
not respond to therapy. Indeed, metastatic or relapsed
forms, even if they can undergo complete remission with
secondary therapy, are often characterized by poor long-
term prognosis and dismal outcome [4-6]. Moreover, chil-
dren who relapse need to be closely monitored for a long
time as anti-cancer therapy side effects may persist or de-
velop months or years after treatment. Therefore, novel
more specific and less toxic treatment approaches, such as
molecular targeted therapies, are under study. Since RMS
cells share characteristics of skeletal muscle precursors, the
most reliable theory about the origin of RMS suggests that
perturbations of the normal mesenchymal development of
the skeletal muscle lineage might have a causative role [7].
Consistently, results from some groups and ours recently
suggest that a differentiation therapy seems to represent an
alternative way to reduce the aggressiveness of cancer cells,
not by exerting cytotoxicity but by restoring the diffe-
rentiation fate of tumor cells [8-12]. Indeed, under specific
treatments, RMS cells progress toward less proliferating
myoblast-like cells that are capable to develop myotube-like
structure. The methyltransferase Polycomb Group (PcG)
protein Enhancer of zeste homolog 2 (EZH2), the catalytic
factor of the Polycomb Repressor Complex 2 (PRC2), re-
presses gene transcription by silencing target genes through
methylation of histone H3 on lysine 27 (H3K27me3)
and it has been shown to prevent cell differentiation
and promote cell proliferation in several tissues [13].
Increasing evidence demonstrates that EZH2 is not
only aberrantly expressed in several types of human
cancers, but often behaves as a molecular biomarker of
poor prognosis [14-21]. EZH2 was clearly shown to act
as a negative regulator of skeletal muscle differentia-
tion favoring the proliferation of myogenic precursors
[22-24]. This function results from an EZH2-dependent
direct repression of genes related to myogenic differenti-
ation [22]. We previously reported that EZH2 is mark-
edly expressed in the RMS context, both in cell lines
and primary tumors compared to their normal counter-
parts [25]. The first evidence of the role of EZH2 as a
main player in the inability of RMS cells to undergo dif-
ferentiation has been recently reported in vitro for the
embryonal RMS cell line RD, established from a tumorrecurrence, through EZH2 genetic silencing upon serum
withdrawal [26].
Here, after having shown that EZH2 was de-regulated
in a cohort of primary embryonal RMS, we evaluated
whether it was possible to boost the differentiation cap-
ability of embryonal RMS RD cells after EZH2 inhibition
even in serum-enriched culture conditions. As an add-
itional promising approach, we investigated whether
pharmacological inhibition of EZH2 in RD cells by either
reducing its expression or catalytically inhibiting its ac-
tivity might be detrimental for cancer cell proliferation
both in vitro and in vivo. Our data demonstrate that EZH2
down-regulation restores the myogenic differentiation of
RD cells with no need to reduce serum (cultured in growth
medium), and that pharmacological inhibition of EZH2 is a
feasible way to restrain the tumor-promoting potential in
embryonal RMS.
Methods
Additional file 1: Supplementary Methods.
Cell lines
RD embryonal RMS cell line was obtained from American
Type Culture Collection (Rockville, MD). A204 and RH18
embryonal RMS cell lines were obtained from Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH
(Braunschweig, Germany). Normal Human Skeletal Muscle
cells (SkMC; myoblasts) were obtained from PromoCell
(Heidelberg Germany).
Nuclear fraction-enrichment
Cells were lysed and assayed as previously reported [10].
Briefly, cells were lysed in cytoplasm lysis buffer A
(10 mM HEPES pH 7.9, 10 mM KCl, 0.2 mM EDTA,
1 mM DTT), containing protease inhibitors, 0.5 mM phe-
nylmethylsulfonylfluoride (PMSF) and 0.6% Nonidet P-40
(Sigma Chemical Co., St Louis, MO, USA). Lysates were
centrifuged at 10.000 rpm 10 min at 4°C and the superna-
tants (cytoplasmic fractions) were split into aliquots and
rapidly frozen. The nuclear pellet was washed in buffer A
without Nonidet P-40 and finally resuspended in nu-
clear lysis buffer B (20 mM HEPES pH 7.9, 0.4 M NaCl,
2 mM EDTA, 1 mM DTT), containing protease inhibi-
tors and 1 mM PMSF (Sigma Chemical Co., St Louis,
MO, USA). Samples were incubated on ice 30 min and
centrifuged at 13.000 rpm 10 min at 4°C; the supernatants
(nuclear fractions) were split into aliquots and rapidly fro-
zen or used for western blot analysis.
Western blotting
Western blotting was performed on whole-cell lysates
and histone extracts as previously described [27,28].
Briefly, cells were lysed in RIPA buffer (50 mM Tris–HCl
pH7.4, 150 mM NaCl, 1 mM EDTA, 1% D.O.C. (Na), 0,1%
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(Sigma Chemical Co., St Louis, MO, USA). Lysates were
sonicated, incubated on ice 30 min and centrifugated at
10,000 g 20 min at 4°C. Supernatants were used as total ly-
sates. Protein concentrations were estimated with the BCA
protein assay (Pierce, Rockford, IL). EZH2 was detected
using the EZH2 antibody (612666; Transduction Laborato-
riesTM, BD, Franklin Lakes, NJ). Antibodies against
Myogenin (F5D) and Myosin Heavy Chain (Meromyosin,
MF20) were obtained from the Developmental Studies
Hybridoma Bank at the University of Iowa (DSHB, Iowa
City, IA). Antibodies against p21Cip1 (sc-397), β-actin (sc-
1616) and all secondary antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA). Antibodies against Troponin I (4002)
were obtained from Cell Signaling (Beverly, MA). The
antibody against the Topoisomerase IIβ was obtained
from Sigma Aldrich (Sigma Chemical Co., St Louis,
MO, USA). Antibody against against Histone 3 (H3),
H3K27me3 (Lys27) and H3K4me3 (Lys4) were obtained
from Millipore (EMD Millipore Corporation, Billerica,
MA, USA). Antibody against α-tubulin (ab4074) was from
Abcam (Cambridge, UK). All the antibodies were used in
accordance with the manufacturer’s instructions.
Histone extraction
Cells were harvested and washed twice with ice-cold
Phosphate Buffered saline (PBS) 1X supplemented with
5 mM Sodium Butyrate and resuspended in Triton Ex-
traction Buffer (TEB: PBS, 0.5% Triton X 100 (v/v)) con-
taining 2 mM PMSF and 0.02% (w/v) NaN3 (107 cells/
ml) and lysated on ice for 10 min. Lysates were centri-
fuged at 2000 rpm for 10 min at 4°C and the pellets were
washed in half volume of TEB and centrifuged.Histones
were extracted O/N at 4°C from pellets resuspended in
0.2 N HCl (4×107 cells/ml). Samples were then centrifuged
and supernatants were used for western blot analysis.
Transient RNA interference
Cells were sequentially transfected by 2 subsequent rounds
(24 h), to secure efficient cell silencing, with ON-
TARGETplus SMART pool siRNA targeting different
regions of the EZH2 transcript (L-004218-00) or non-
targeting siRNA (control; D-001206-13), previously
validated in other publications [14,29,30] (both from
Dharmacon, Thermo Fisher Scientific, Lafayette, CO).
Real time qRT-PCR
Total RNA was extracted using TRizol (Invitrogen,
Carlsbad, CA) and analyzed by real-time RT-qPCR for
relative quantification of gene expression [27] using
Taqman gene assays (Applied Biosystems, Life Techno-
logies, Carlsbad, CA) for GAPDH (Hs99999905_m1),
EZH2 (Hs01016789_m1), Myogenin (Hs01072232_m1),MCK (Hs00176490_m1) and p21 (Hs00355782_m1). For
the relative quantification of Murine Ezh2 and MHC
mRNA the SYBR-green method was used (Applied Bio-
systems, Life Technologies, Carlsbad, CA) with primers
previously reported [31] or available on request. The
values were normalized to the levels of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA. An Ap-
plied Biosystems 7900HT Fast Real-Time PCR System
(Applied Biosystems, Life Technologies, Carlsbad, CA)
was used for measurements.
Murine Ezh2 over-expression
Flag-tagged murine Ezh2, cloned into the pMSCV retro-
viral vector (Addgene, Cambridge, MA) or control
empty vector, both co-expressing the Green Fluorescent
Protein (GFP) as reporter gene, were kindly obtained
from G. Caretti. Phoenix ampho cells were obtained
from ATCC and cultured in DMEM supplemented with
10% FBS (growth medium, GM).Transient transfection
of Phoenix ampho cells were performed using lipofecta-
mine reagent (Invitrogen, Carlsbad, MA) and viral parti-
cles were collected after 48 h. Supernatant containing
viral particles were used to infect RD cells O/N in the
presence of 8 ug/ml of polybrene.
Immunofluorescence for MHC detection
Immunofluorescence to visualize MHC was performed
as previously described using the MF-20 antibody (De-
velopmental Studies Hybridoma Bank at the University
of Iowa, Iowa City, IA) [10]. Briefly, cells were washed 3
times in PBS, fixed 10 min in 4% PFA and permealized
5 min with 0.2% Triton X-100 in PBS. After 30 min in
PBS containing 3% bovine serum albumin, slides were
incubated 1 h at room temperature with the MF-20
antibody against myosin heavy chain (MHC; Develop-
mental Studies Hybridoma Bank at the University of
Iowa, Iowa City, IA). After 2 washing in PBS, cells were
treated with a rhodamine-conjugated secondary anti-
body (Millipore, Temecula, CA). After being counter-
stained with DAPI, chamber slides were mounted in
GelMount (Biomeda, Foster City, CA, USA). Images were
acquired with an Eclipse E600 fluorescence microscope,
through LUCIA software version 4.81 (Nikon, Sesto
Fiorentino, Firenze, Italy).
Cell cycle and apoptosis assays
Cells were transfected 24 h after seeding (Day 0) with
siRNAs and after 24 h transfected again. Then, they
were harvested and counted at the reported time points.
For pharmacological treatments RD cells were treated
with the S-adenosyl-L-homocysteine hydrolase inhibitor
3-Deazaneplanocin A (DZNep) and MC1945 for 24 h,
48 h, 72 h and 96 h. For cell cycle assay, cells were har-
vested by trypsinization at the indicated time points,
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one/methanol (1:4 v/v) for at least 1 h and, after removing
alcoholic fixative, stained in the dark with a solution con-
taining 50 μg/ml Propidium Iodide (PI) and 100 μg/ml
RNase (Sigma) for 30 min at room temperature. For quan-
tification of apoptosis, cells were harvested, washed twice
with ice-cold PBS and stained in calcium-binding buffer
with APC-conjugated Annexin V and 7-Aminoactinomycin
D (7-AAD) using Annexin V apoptosis detection kit (BD
Pharmingen, San Diego, CA), according to manufacturer’s
recommendations. Samples were analyzed within 1 h. The
stained cells were analyzed for both cell cycle and apoptosis
by fluorescence-activated cell sorting using a FACSCantoII
equipped with a FACSDiva 6.1 CellQuest software (Becton
Dickinson Instrument, San Josè, CA).
Chromatin immunoprecipitation (ChIP)
ChIP assay was performed as previously described (70) with
minor modifications. Briefly, chromatin was cross-linked in
1% formaldehyde for 15 min at room temperature and
quenched by addition of glycine at 125 mM final concen-
tration for 5 min at room temperature before being placed
on ice. Cells were washed twice with ice-cold PBS contain-
ing 1 mM PMSF and 1X protease inhibitors, resuspended
in ice-cold cell lysis buffer (10 mM Tris–HCl pH 8, 10 mM
NaCl, 0.2% NP-40, 1 mM PMSF and 1X protease inhibi-
tors) and incubated on ice for 20 minutes. After centrifuga-
tion at 4000 rpm for 5 min, nuclei were resuspended in ice-
cold nuclear lysis buffer (50 mM TrisHCl pH 8.1; 10 mM
EDTA; 1% SDS, 1 mM PMSF and 1X protease inhibitors)
and left on ice for 10 min. Chromatin was then sonicated
to an average fragment size of 200–300 bp using a Biorup-
tor and diluted ten times with IP dilution buffer (16.7 mM
Tris–HCl pH 8.1, 167 mM NaCl, 1.2 mM EDTA, 0.01%
SDS, 1.1% Triton X-100, 1 mM PMSF and 1X protease in-
hibitors). Diluted chromatin was pre-cleared using protein
G-agarose magnetic beads (Invitrogen) for 1 hour at 4°C
and incubated with the corresponding antibodies O/N at
4°C. The following antibodies were used: anti-acetylated
histone H3, anti-trimethyl Lysine 27 histone H3 and anti-
trimethyl Lysine 4 histone H3 (EMD Millipore Corpor-
ation, Billerica, MA, USA) and anti-Ezh2 (Diagenode s.a.
Liège, Belgium). Immunoprecipitated chromatin was recov-
ered by incubation with protein G-agarose magnetic beads
(Invitrogen, Carlsbad, CA) for 2 hours at 4°C. Beads were
washed twice with low salt washing buffer (20 mM
Tris–HCl pH8, 2 mM EDTA, 1% Triton X-100, 0.1%
SDS, 150 mM NaCl), twice with high salt washing buffer
(20 mM Tris–HCl pH8, 2 mM EDTA, 1% Triton X-100,
0.1% SDS, 500 mM NaCl) and twice with TE before in-
cubating them with elution buffer (10 mM Tris–HCl
pH8 1 mM EDTA, 1% SDS) for 30 minutes at 65°C.
Cross-linking was then reverted O/N at 65°C and sam-
ples were treated with proteinase K for 2 hours at 42°C.The DNA was finally purified by phenol: chloroform ex-
traction in the presence of 0.4 M LiCl and ethanol precipi-
tated. Purified DNA was resuspended in 50 μl of water.
Real-time PCR was performed on input samples and
equivalent amounts of immunoprecipitated material with
the SYBR Green Master Mix (Applied Biosystems, Life
Technologies, Carlsbad, CA). Primer sequences are avai-
lable on request.
Xenograft experiments and immunohistochemistry
Athymic 6-week-old female BALB/c nude mice (nu +
\nu+) were purchased from Charles River. Procedures
involving animals and their care were conformed to in-
stitutional guidelines that comply with national and
international laws and policies (EEC Council Directive
86\609, OJ L 358, 12 December 1987). RD cell suspen-
sions in PBS (10×106 cells in 100 μl) were injected sub-
cutaneously into the posterior flanks of nude mice.
When the tumors became palpable, i.e., about approxi-
mately 70–80 mm3, mice were intraperitoneally injected
with MC1945 (2.5 mg/Kg) or control vehicle (DMSO)
twice daily, 3 days per week for 3 weeks when mice were
sacrificed. No visible signs of toxicity such as weight loss
or behavioral change were seen with the compound dose
and treatment timing used, as already reported [32,33].
Tumor volume was measured by caliper with the follow-
ing formula: tumor volume (mm3) = L × S2 × π/6
wherein L is the longest and S the shorter diameter and
π/6 is a constant to calculate the volume of an ellipsoid,
as described [10]. Representative tumor growth data
were obtained from 3 mice per treatment/group. In a
parallel experiment, 3 mice per treatment/group were
sacrificed 12 days after the first treatment, i.e. the expo-
nential tumor growth phase, and xenografts removed
after tumor volume measurement. Portions of the ex-
cised tumors embedded in paraffin were used for immu-
nohistochemical analysis. Sections of 10 μm cut from
xenograft blocks were stained with hematoxylin/eosin.
Five μm serial sections were subjected to immunohisto-
chemistry for the expression of EZH2 and Ki67 with
methods and antibodies reported below for primary hu-
man RMS samples. The MF-20 antibody (DSHB, USA)
was used to detect the expression of MHC. Counterstain-
ing was carried out with Gill’s hematoxyline (Bio-Optica,
MI, Italy). Sections were dehydrated and mounted in non-
aqueous mounting medium. Images were acquired under
an Eclipse E600 microscope (Nikon) through the LUCIA
software, version 4.81 (Nikon) with a Nikon Digital Cam-
era DXM1200F.
Immunohistochemistry on RMS primary tissues
Archival, de-identified formalin-fixed, paraffin-embedded
RMS and control tissues were obtained from the Depart-
ment of Pathology of Ospedale Pediatrico Bambino Gesù
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Boards. Clinicopathological characteristics of the cohort
are reported in Table 1. Histopathological features of the
tumors were reviewed for the present study by a Patholo-
gist (R. B) blinded to the results of immunohistochemical
analysis. Sections from RMS samples and 3 control muscle
tissues were cut at 3–5 μM, deparaffinized in xylene and
rehydrated through graded ethanol. Antigen retrieval was
performed for 25 min at 98°C. After endogenous peroxid-
ase blocking with 3% H2O2 in Tris-buffered saline (TBS)
for 30 min at room temperature (RT), 3% to 5% BSA in
TBS was applied for 1 hour at room temperature for non-
specific background blocking. Sections were treated withTable 1 Clinical and histopathological features of
pediatric patients with embryonal rhabdomyosarcoma
(RMS) (n=19)





< 10 14 (74)
≥ 10 5 (26)
Localisation
Orbit-genitourinary tract-head and neck$ 9 (47)
Cranial paramenigeal-extremity-other$$ 10 (53)
Tumor volume
< 5 cm 7 (37)
















EZH2 (positive cells/microscopic field) 40 (range 29-44)
Ki67 (positive cells/microscopic field) 20 (range 17-29)
Abbreviations: DOD dead of disease, IRS Intergroup Rhabdomyosarcoma Study
Group staging system.
$Favorable and $$Unfavorable tumor localization.Biotin Blocking System (DAKO, Carpinteria, CA) for add-
itional blocking, according to the manufacturer’s instruc-
tions. Sections were incubated with primary antibodies for
EZH2 (Transduction LaboratoriesTM, BD, Franklin Lakes,
NJ), as reported [34] and Ki67 (Novocastra; Newcastle
upon Tyne, UK), and then with secondary antibodies EnVi-
sion System-HRP (Power vision Plus method, Zymed, San
Francisco, CA, USA) and Biotinilated link (DAKO,
Carpintera, CA), respectively. Positive reactions were visu-
alized by staining with 3-amino-9-ethylcarbazolo (AEC)
and 3,3′-diamminobenzidine (DAB) (DAKO Carpintera,
CA), respectively, and then sections were slightly counter-
stained with Gill’s hematoxylin (Bio-Optica, Milan, Italy).
Negative controls were stained in parallel by treating
serial cross-sections simultaneously either with isotype
non-specific IgG or omitting the primary antibody.
Positive staining was defined as well-localized nuclear
pattern. Levels of expression were semi-quantitatively
quantified by scoring the percentage of positive nuclei
stained for each specific molecule per microscopic field
in at least 5 fields per section by 2 blinded observers
and, in rare cases of discrepancy, by an additional third
independent observer. Differences in intensity of immu-
noreactivity were not taken into account. Each section
was scored using an Eclipse E600 microscope (Nikon,
Sesto Fiorentino, Firenze, Italy) at 400× magnification.
Images were acquired through LUCIA software, version
4.81 (Nikon, Sesto Fiorentino, Firenze, Italy) with a Nikon
Digital Camera DXM1200F.Statistical analysis
The Student’s t-test was done to assess the difference
between various treatments. Statistical significance was
set at a two-tailed P value less than 0.05. All analyses
were performed with SPSS 11.5.1 for Windows Package
(© SPSS, Inc., 1989–2002 and © LEADTOOLS 1991–
2000, LEAD Technologies, Inc., Chicago, IL).Results
EZH2 protein is expressed in embryonal RMS
primary tumors
Previously, our and other groups reported that the
expression of EZH2 mRNA in embryonal RMS pri-
mary tumors was markedly expressed while was not
detectable in muscle tissues [25,35]. Here, we semi-
quantitatively analyzed the expression of EZH2 pro-
tein by immunohistochemistry in 19 embryonal RMS
primary tumors (Table 1). Strikingly, EZH2 was expressed
in the nuclei of all the RMS specimens tested that are also
positive for the nuclear expression of the proliferative
marker Ki67 (Table 1 and Figure 1). By contrast, normal
control muscles were negative for both markers (Figure 1).
These findings indicate that also the expression of EZH2
Figure 1 EZH2 protein levels are up-regulated in primary embryonal rhabdomyosarcoma (RMS) tissues. Representative immunohistochemical
staining showing EZH2 (upper panels) and Ki67 (bottom panels) expression in sections of normal muscle and primary tumor tissue of two embryonal
RMS specimens (RMS1 and RMS2). Brown-orange color in nuclei indicates positive staining (400× Magnification). Normal muscles are negative for both
markers. Insets represent higher magnification of selected regions.
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tumors.
Down-regulation of EZH2 reduces embryonal RMS
cell proliferation
We then evaluated the expression of EZH2 in 3 embry-
onal RMS cell lines. In agreement with results in pri-
mary samples, EZH2 expression is remarkably higher in
these cell lines compared to control skeletal muscle pre-
cursors (SKMC), all cultured in a growth factor-enriched
medium (supplemented with 10% serum) (Figure 2a).
In particular, EZH2 appeared mostly localized in the
nucleus (Figure 2b).
To define whether EZH2 was required to sustain em-
bryonal RMS proliferation, as it occurs for other kind of
human cancers [36,37], cell proliferation of the established
embryonal RMS cell line RD, derived from a tumor re-
currence [38], and cultured in growth medium, i.e. sup-
plemented with 10% serum, was evaluated upon EZH2
genetic silencing. After two consecutive rounds of RNA
interference with siRNAs against EZH2, the level of
EZH2 protein expression in RD cells decreased more
than 80% starting from 24 h after the first siRNA trans-
fection (Figure 2d). In this condition, EZH2 knockdown
in RD cells resulted in 36 ± 6% and 48 ± 8% inhibition of
cell proliferation at day 3 and 4, respectively, compared
to cells treated with a non-targeting control siRNA
(Figure 2c). We confirmed the anti-proliferative effect
of EZH2 siRNA with MTT assay (Additional file 2:
Figure S1). To ascertain that the growth inhibition was
the result of a reduced activity of EZH2, we analyzed
the methylation status of Lys 27 on histone H3. More-
over, the Lys 4, a residue not methylated by EZH2, was
also evaluated for methylation. We observed a global
decrease of trimethylated Lys 27 (H3K27me3), but notof trimethylated Lys 4 (H3K4me3) at day 3 post-EZH2
siRNA transfection (Figure 2e), suggesting that EZH2-
dependent histone methylation was specifically im-
paired upon EZH2 siRNA. These results indicate that
over-expressed EZH2 sustains proliferation in embry-
onal RMS cells.
Down-regulation of EZH2 is sufficient to restore embryonal
RMS cell myogenic differentiation in growth medium
Recent data showed that EZH2 down-regulation in RD
cells induces partial recovery of myocyte phenotype after
serum withdrawal [26]. Because of the inhibitory role
of EZH2 in physiological myogenic differentiation, we
asked whether the observed impaired proliferation of
EZH2-depleted RD cells might be paralleled with the re-
covery of the myogenic fate even in the presence of 10%
serum. We therefore set up differentiation assays on RD
cells in the same culture condition of the proliferation
assays, i.e. in growth medium, and analyzed the expres-
sion of differentiation markers. Six days after EZH2
siRNA transfection, multinucleated myotube-like struc-
tures positive for Myosin Heavy Chain (MHC) along
with the expression of the skeletal muscle protein Tropo-
nin I, both indicative of terminal myogenic differentiation,
were detected in EZH2-depleted RD cells compared to
control siRNA cells (Figure 3a and 3b). Consistently,
EZH2 knockdown induced the over-expression of both
Myogenin and cyclin-dependent kinase inhibitor p21Cip1
(Figure 3c). Up-regulation of both Myogenin and the
late differentiation marker Muscle Creatine Kinase
(MCK) mRNA was detected as soon as 48 h post-EZH2
siRNA treatment, and was markedly enhanced after
72 h (Figure 3d). In line with the known inability of RD
cells to undergo skeletal muscle-like differentiation under
myogenic cues, the differentiation medium (low serum)
Figure 2 EZH2 depletion inhibits embryonal rhabdomyosarcoma (RMS) cell proliferation. (a) Western blot showing EZH2 and β-actin
(loading control) in whole-cell lysates from embryonal RMS cell lines and normal human myoblasts SKMC as control, all cultured in proliferating
growth medium (GM, i.e., supplemented with 10% fetal calf serum). EZH2* band: longer exposition. Representative of three independent
experiments. (b) Western blot analysis of nuclear (N) and cytoplasmic (C) -enriched cell fractions of embryonal RMS cell lines. Nuclear EZH2 was
detected in all cell lines. β-actin and topoisomerase IIβ were used as loading controls to discriminate the cytoplasmic and nuclear-enriched cell
fractions, respectively. Representative of two independent experiments. (c) RD cells were transfected (Day 0) with EZH2 siRNA or control (CTR)
siRNA and after 24 h transfected again (Day 1). Cells cultured in proliferating growth medium (GM, i.e. supplemented with 10% of fetal calf serum)
were harvested and counted starting from 24 h from the first siRNA trasfection at the indicated time points. *P < 0.05 (Student’s t-test).
Results from three independent experiments are shown; Bars, Standard Deviation (SD). (d) Western blot showing levels of EZH2 24 h and 48 h
post-transfection with CTR or EZH2 siRNA in RD cells. β-actin served as loading control. Representative of four independent experiments.
(e) Western blot showing histone H3 trimethylation on Lys27 (H3K27me3) and on Lys4 (H3K4me3) status 72 h after EZH2 or CTR siRNA
transfection. Histone H3 was the loading control. Representative of three independent experiments.
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sion of Myogenin and the formation of MHC-positive
multinucleated structures 72 h and 5 days post-siRNA
transfection, respectively, as compared to growth (10%
serum) medium condition (Additional file 3: Figure S2a
and c). Similar results were obtained transfecting RD cells
with a previously published siRNA that targets the 5′UTR
of the endogenous EZH2 [31] (Additional file 3: Figure
S2b and d), confirming EZH2 silencing-dependent effects.
In addition, RD cells were stably infected with a lentiviral
vector expressing a short hairpin (sh)RNA against EZH2.
Lentivirus-mediated EZH2 shRNA expression phenocopies
the effects of EZH2 depletion by siRNA inducing the
de-repression of p21Cip1, Myogenin and MCK genes,
together with cell elongation and fusion to form multi-
nucleated MHC-positive fibers compared to control
shRNA (Additional file 4: Figure S3). To determine
whether EZH2 directly represses muscle gene expres-
sion even in RD cells, as previously shown in myoblasts
and RD cells in differentiation medium [22,23,26], we
carried out ChIP assays to evaluate the binding ofEZH2 and the Lys 27 histone H3 trimethylation status
on muscle-specific loci. Figure 3e shows that EZH2 re-
cruitment to regulatory regions of both early (i.e.,
Myogenin) and late (MCK and MHC) muscle-specific
genes decreased in EZH2-silenced cells as compared
to cells transfected with control siRNA. This corre-
lated with a decrease in the levels of H3K27me3 at the
indicated regulatory loci. Interestingly, the enrichment
of EZH2 on late muscle genes (MHC and MCK) was
10-fold higher than those on the Myogenin locus
under steady-state conditions (data not shown). This
observation is consistent with the fact that RMS cells spon-
taneously express Myogenin, while they fail to produce
MCK even when cultured in differentiation medium [8,9].
The functional effects of EZH2 knockdown on muscle
genes and p21Cip1 expression were reverted by over-
expression of a flag-tagged mouse Ezh2, indicating that
they were specific for EZH2 (Figure 4). Altogether these
results suggest that blocking EZH2 in actively growing
embryonal RMS RD cells is a way to boost their cell-
cycle exit to recover myogenic differentiation.
Figure 3 Depletion of EZH2 results in myogenic differentiation of embryonal RD cells in growth medium (GM). RD cells were transfected
(t0) with EZH2 siRNA or control (CTR) siRNA and after 24 h silenced again. They were cultured in proliferating growth medium (GM, i.e. supplemented
with 10% of fetal calf serum) for the following experimental procedures. (a) RD cells were analyzed for the induction of muscle-like differentiation 6 days
post-siRNA transfection. Representative immunofluorescence showing de novo expression of endogenous Myosin Heavy Chain (MHC, red) in
multinucleated fibers of EZH2 siRNA-transfected cells. DAPI was used for nuclear staining. Representative of four assays. (b) Western blot
showing de novo expression of Troponin I 6 days post-siRNA transfection. GAPDH served as loading control. (c) Western blot showing EZH2,
p21Cip1, Myogenin and GAPDH expression in RD cells 48 h and 72 h after EZH2 or CTR siRNA transfection and in untreated RD cells. (*band:
longer exposure). Representative of four independent experiments. GAPDH served as loading control. (d) mRNA levels (real time qRT-PCR) of
Myogenin, MCK, and p21Cip1 in RD cells 48 h and 72 h after EZH2 siRNA treatment were normalized to GAPDH levels and expressed as fold
increase over untreated condition (1 arbitrary unit, not reported). Columns, means; Bars, SD. Results from three independent experiments are
shown. *P < 0.05 (Student’s t-test). (e) ChIP assays on RD cells 72 h after EZH2 or CTR siRNA transfection showing the recruitment of EZH2 and
the levels of histone H3 trimethylation on Lys27 (H3K27me3) on Myogenin, MCK, MHC and SMAD6 (as negative control) regulatory regions.
Normal rabbit IgG were used as negative control. Graphs represent the percent of immunoprecipitated material relative to input DNA. Results
are the average of three independent experiments. *P <0.05 (Student’s t-test).
Ciarapica et al. BMC Cancer 2014, 14:139 Page 8 of 15
http://www.biomedcentral.com/1471-2407/14/139Pharmacological inhibition of EZH2 prevents embryonal
RMS cell proliferation
To translate our results toward a future potential clinical
intervention for aggressive embryonal RMS, we assessed
the feasibility of pharmacological inhibition of EZH2 in
RD cells. We treated RD cells with a well known EZH2
inhibitor, the S-adenosyl-L-homocysteine hydrolase in-
hibitor 3-Deazaneplanocin A (DZNep), which inducesdegradation of EZH2 [17,31,39]. In parallel, we used two
new catalytic EZH2 inhibitors that inhibit the activity of the
protein, the already validated EZH2 inhibitor MC1948 [28]
and a new, more potent, derivative, MC1945 [32,40]. A
significant reduction in the proliferation rate was no-
ticed in RD cells treated for 72 h and 96 h with 1 μM of
either DZNep or MC1945 compared to untreated or
vehicle-treated cells (Figure 5a). Moreover, a significant
Figure 4 Functional rescue of EZH2 depletion-dependent effects by overexpression of a murine Ezh2 in RD cells. (a) mRNA levels (real
time qRT-PCR) of p21Cip1, Myogenin and MHC in RD cells treated with CTR and EZH2 siRNA and then infected with a murine version of EZH2
(mEzh2) were normalized to GAPDH levels and expressed as fold increase over uninfected condition (1 arbitrary unit, not reported). mRNA levels
of both human EZH2 (hEZH2) and murine EZH2 (mEzh2) are shown. Columns, means; Bars, SD. Results from three independent experiments are
shown. *P < 0.05 (Student’s t-test). (b) Western blotting showing the rescuing effects of the overexpression of a murine EZH2 variant (mEzh2) on
the levels of myogenin and p21Cip1 in RD cells previously treated with both CTR and EZH2 siRNA. α-tubulin was used as loading control.
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RD cells were treated with 5 μM of each compound, sug-
gesting a dose-dependent inhibitory effect (Figure 5a).
These effects were accompanied by a down-regulation of
EZH2 protein levels upon DZNep treatment (Figure 5b, left
panel) whereas the levels remained constant after treat-
ment with the catalytic inhibitors MC1945, as expected
(Figure 5b, right panel) [28]. Both DZNep and MC1945
treatments resulted in a decrease in global levels of the
EZH2 repressive mark H3K27me3 (Figure 5b) (28–30). OnFigure 5 Pharmacological inhibition of EZH2 prevents embryonal RM
medium (GM, i.e. supplemented with 10% of fetal calf serum) were treated
3-deazaneplanocin A (DZNep) (left panels) or the EZH2 catalytic inhibitor MC1
water for DZNep or DMSO for MC1945) and harvested and counted at the
independent experiments in duplicate. (b) Western blot showing EZH2 alon
(H3K9me3) levels in RD cells treated for 72 h with 5 μM DZNep (left panel)
Total H3 and - tubulin amounts were shown as the loading controls. Reprethe contrary, the levels of H3K9me3, another repressive
mark, remained unchanged after both treatments, dem-
onstrating the specificity of the two compounds in tar-
geting EZH2-containing complexes in our experimental
conditions (Figure 5b). Same results were obtained in pre-
liminary experiments with MC1948 (Additional file 5:
Figure S4a and b). Similarly to what happened for EZH2-
silenced cells, culture condition in differentiation medium
(low serum) was unable to significantly potentiate the for-
mation of MHC-positive multinucleated structures 4 daysS cell proliferation. (a) RD cells cultured in proliferating growth
daily with either the S-adenosyl-L-homocysteine hydrolase inhibitor
945 (right panels) at the reported concentrations or with vehicle (i.e.,
indicated time points. *P < 0.05 (Student’s t-test); Bars, SD. Three
g with histone H3 trimethylation on Lys27 (H3K27me3), and on Lys9
and 5 μM MC1945 (right panel) or with vehicle (i.e., water or DMSO).
sentative of three independent experiments.
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medium condition (Additional file 6: Figure S5). By con-
trast, 5 days of treatment in DM lead to detachment of
cells from the well surface, maybe due to cytotoxic ef-
fects of nutrient-deprived conditions (data not shown).
Altogether, these findings clearly suggest that phar-
macological inhibition of EZH2 affects the proliferative
potential of embryonal RMS cells and phenocopies the
cell-specific effect of siRNA-mediated EZH2 depletion.Figure 6 Pharmacological inhibition of EZH2 restores myogenic differ
medium (GM). RD cells were analyzed for the induction of muscle-like diff
Representative immunofluorescence showing de novo expression of endog
DZNep and MC1945 treated RD cells. Untreated (UN) and control cells trea
immunofluorescence of three assays. mRNA levels (real time qRT-PCR) of M
5 μM MC1954 (d) were normalized to GAPDH levels and expressed as fold
Columns, means; Bars, SD. Results from two independent experiments are
MC1945 (right) at the indicated concentrations were stained for Annexin V
labeling (% cell death) was recorded by flow cytometry. Representative cyt
quadrants) represent early stages of apoptosis, whereas Annexin V+/7-AAD
Representative of three independent experiments run in duplicate.Pharmacological inhibition of EZH2 restores myogenic
differentiation of embryonal RMS cells even in the
presence of growth medium
In order to evaluate whether the strong inhibitory effects
on RD proliferation obtained by blocking EZH2 methyl-
transferase activity was associated to the triggering of
myogenic-like differentiation we treated RD cells with
1 μM of MC1948 for 6 days and then we analyzed myo-
genic differentiation by immunocytochemistry. We noticedentiation of embryonal RMS cells in the presence of growth
erentiation after 6 days of 5 μM DZNep (a) and MC1945 (c) treatments.
enous Myosin Heavy Chain (MHC, red) in multinucleated fibers of
ted with vehicle (i.e., water or DMSO) are shown. Representative
yogenin and MCK in RD treated for 72 h with 5 μM DZNep (b) and
increase over Untreated condition (1 arbitrary unit, not reported).
shown. (e) RD cells Untreated or treated for 96 h with DZNep (left) or
and 7-AAD, and the frequency of Annexin V and 7-AAD-positive
ofluorometric plots are shown. Annexin V+/7-AAD- events (lower right
+ events (upper right quadrants) stand for late apoptotic cells.
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expressing MHC in RD cells treated with MC1948 com-
pared to vehicle-treated cells (Additional file 4: Figure S3c).
Then we extended the study enrolling DZNep and
MC1945. Treatment of RD cells for 6 days with either
5 μM of DZNep or MC1945 resulted in the formation
of MHC-positive multinucleated myotube-like struc-
tures (Figure 6a and 6c) and in the induction of Myo-
genin and MCK gene transcription 72 h post-treatment
(Figure 6b and 6d). Consistently with these results, no
sign of apoptosis testified by the lack of appearance of
apoptotic Annexin V-positive cells was evidenced in
both DZNep- and MC1945-treated RD cells (Figure 6e).
Altogether, these results suggest that the two pharma-
cological inhibitory approaches of EZH2 function areFigure 7 Analysis of pharmacological inhibition of EZH2 in vivo. RD ce
the posterior flanks of athymic 6-week-old female BALB/c nude mice (nu +
after the initial inoculation when they reached approximately 70–80 mm3,
control vehicle (DMSO) twice daily, 3 days per week for 3 weeks when mic
measured by caliper weekly for 21 days (right) after which xenografts were
of mice were sacrificed at day 12 of treatment, during the exponential tumor
caliper prior to the initiation of treatment and at the time of sacrifice. (b, left)
DMSO (a, b, c) as controls. (b, right) Portions of the excised tumors in (b) were
in liquid N2. Histogram reports tumor volumes of each xenograft. (c) Sections
Five μm serial sections were subjected to immunohistochemistry for the expr
left panels) and MHC (OCT embedded, staining with the MF-20 antibody, cyto
and MC1945 treated (lower panels) sections from RD xenografts. Counterstain
were dehydrated and mounted in mounting medium. Images were acquired
version 4.81 (Nikon) with a Nikon Digital Camera DXM1200F.capable to restore myogenic differentiation of embry-
onal RMS cells as occurs in the case of EZH2 genetic
depletion.
Pharmacological inhibition of EZH2 induces myogenic
differentiation in embryonal RMS tumor xenografts
To verify that inhibiting EZH2 with the catalytic inhibitor
MC1945 might reduce RMS cell proliferation and con-
comitantly induce myogenic differentiation even in vivo,
we injected nude mice subcutaneously with RD cells and,
when tumors began palpable, intraperitoneally injected
them with 2.5 mg/kg of MC1945 or with vehicle (DMSO).
MC1945 treatment resulted in a significant reduction in
xenograft tumor growth after 3 weeks (Figure 7a). The
myogenic differentiation was analyzed in xenografts excisedll suspensions in PBS (10×106 cells) were injected subcutaneously into
\nu+). (a) As soon as the tumors became palpable, i.e., about 2 months
mice were intraperitoneally injected with MC1945 (2.5 mg/Kg) or
e were sacrificed with no visible signs of toxicity. Tumor volume was
surgically removed (left). (b) for immunohistochemical studies, a group
growth phase, and xenografts excised. Tumor volume was measured by
xenografts from either nude mice treated with MC1945 (d, e, f) or with
embedded in paraffin for immunohistochemical analysis or snap-frozen
of 10 μm cut from xenograft blocks were stained with hematoxylin/eosin.
ession of EZH2 and Ki67 (paraffin-embedded, nuclear orange staining in
plasmic orange staining in right panels) of serial DMSO (upper panels)
ing was carried out with Gill’s hematoxyline (Bio-Optica, MI, Italy). Sections
under an Eclipse E600 microscope (Nikon) through the LUCIA software,
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ponential growth phase (Figure 7b and c). The effects of
the EZH2 inhibitor were anti-proliferative, as demonstrated
by the retardation of tumor growth (Figure 7a and b) asso-
ciated to a reduction of the proliferative marker Ki67 in
tumor xenografts (Figure 7c, left panel), and led to de novo
expression of fibers positive for Myosin Heavy Chain
(MHC) compared to vehicle treatment (Figure 7c, right
panel). These findings provide evidence that it is possible to
pharmacologically counteract the tumorigenic function of
EZH2 in vivo, and that the treatment could promote a
more differentiated phenotype directly into the tumor bulk.
Discussion
In the last decade, to trace the way for developing in-
novative anti-cancer therapies, several groups focused
their pre-clinical research on the modulation of epigen-
etic regulators often aberrantly expressed in cancer. Due
to the fact that epigenetic processes are key players in
cell tissue specification during the embryonal life, this
approach seems to be particularly captivating for those
cancers, such as pediatric embryonal RMS, in which the
pathogenic mechanisms involve the deregulation of genes
controlling the lineage commitment [41]. Among these, the
histone methyltransferase EZH2 is a fundamental negative
regulator of myogenic precursor differentiation by re-
pressing the expression of myogenic genes through the
H3K27me3 mark deposition on the promoters of myo-
genic genes [22,28]. We recently reported that EZH2
transcripts were aberrantly expressed in both embryonal
RMS primary tumors and in the RD cell line [25,35]. In
this study, we report that, as for transcripts, EZH2 pro-
tein is aberrantly over-expressed in 19 out of 19 embry-
onal RMS primary tumors compared to normal muscle
tissues, thus indicating that the high level of expression
of EZH2 is a common molecular lesion of embryonal
RMS neoplasia.
Moreover, a recent report indicates that the RD cell
line, derived from an embryonal RMS local recurrence
and thus representative of an aggressive tumor [38], may
reactivate muscle-specific genes and develop a partial re-
covery of myocyte phenotype following EZH2 knock-
down when depleted of serum [26]. We show here that
it is possible to revert the tumor phenotype of the RD
cell line by silencing EZH2 even under proliferative
stimuli such as in a serum-enriched molecular context.
The final result is the acquisition of a myogenic pheno-
type, by the de-repression of myogenic genes Myogenin
and MCK, which can be rescued by the over-expression
of a murine Ezh2 not targeted by the used siRNA oligos.
More importantly, as a proof-of-concept we report that
in these pro-proliferative conditions, pharmacological in-
hibition of EZH2 by two different approaches, i.e. by de-
creasing its availability or hampering its activity, is capableto prevent the proliferation and allow the recovery of
myogenic differentiation of these cells in vitro and in vivo.
In line with the inability of RD cells to undergo terminal
differentiation in conditions that induce myotube forma-
tion in normal, non-tumorigenic, myoblasts (REF), low-
serum differentiation medium did not potentiate the effect
of EZH2 depletion/inactivation on the myogenic-like char-
acteristics vs growth medium. Consistently, EZH2 expres-
sion is not modulated by serum deprivation in RD cells
(data not shown). Small molecule inhibitors of histone
methyltransferases are emerging [42] and a number of
novel EZH2 inhibitors are under preclinical evaluation in
other types of cancer [43-45].
Here we treated RD RMS cells with the prototype in-
hibitor of PRC2, deazaneplanocin A (DZNep), which
acts through an indirect mechanism by reducing the
level of EZH2 protein [17,46]. Recently, DZNep has been
reported to be effective in several preclinical studies fa-
voring apoptosis and/or differentiation of tumor cells
[39,47-49]. We found that DZNep arrested RD prolifera-
tion in a dose-dependent manner with a concomitant
down-regulation of EZH2 protein levels and a decrease
in global levels of H3K27me3, while the levels of the
other repressive mark H3K9me3 remained unchanged,
suggesting an EZH2-specific effect at the doses utilized.
Strikingly, in the same growth condition DZNep induced
the appearance of MHC-positive multinucleated
myotube-like structure in RD cells, accompanied by the
activation of myogenic genes such as Myogenin and
MCK, and with no signs of apoptosis. The observation
that in RMS DZNep induces myogenic differentiation
instead of apoptosis, the general effect that DZNep has
in other human cancer, suggests that its inhibition to-
ward EZH2 is quite specific being pro-differentiative.
However, since DZNep may affect other methyltransfer-
ases, we enrolled in our study also two molecules be-
longing to a new class of catalytic inhibitors, validated
against a panel of histone methyltransferases [32,40],
MC1948, which has been already validate as EZH2 in-
hibitor in myoblasts [28] and a new, more effective, de-
rivative, MC1945. Both MC inhibitors phenocopied the
effects of DZNep and EZH2 genetic depletion in vitro,
indicating a common mechanism of action. More im-
portantly we observed that MC1945 was able to restrain
tumor growth of RD xenografts in nude mice inducing
tumor cells differentiation in vivo. Pharmacological inhib-
ition of EZH2 by using a new EZH2 inhibitor has been re-
cently shown to induce anti-tumoral effects in malignant
rhabdoid tumor (MRT) cells deleted for SMARCB1 [50].
Importantly, this result highlights the dependency of
SMARCB1-mutant/deleted MRT tumorigenicity on EZH2.
However, the Authors showed no effects of the inhibitor on
SMARCB1-wild-type RD cells that were cultured in
medium replenished with the drug on day 4 [50]. Differently,
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day since this approach was defined as effective during
preliminary experiments. As a consequence, in our ex-
perimental protocol tumor cells were in contact with
fresh drug each 24 h. These diverse approaches could
be responsible for the difference in the response to
pharmacological inhibitors.
In summary, here we present a preclinical study in
which the experimental evidence indicates that the
pharmacological targeting of EZH2 might represent a
way to reduce the aggressiveness of RMS, promoting a
more differentiated phenotype and thus enlarging the
scenery of the future clinical intervention to treat this
type of tumors.
Conclusions
Collectively our data provide evidence that EZH2 abnor-
mal over-expression is responsible for both sustaining
proliferation and inhibiting myogenic differentiation of
embryonal RMS. More importantly, our results indicate
that pharmacological targeting of EZH2 might represent
a potential feasible approach to be used as adjuvant
treatment for making conventional therapy more effect-
ive on less aggressive and more differentiated RMS.
Additional files
Additional file 1: Supplementary Materials and Methods.
Additional file 2: Figure S1. Biochemical analysis of cell viability using
MTT assay shows the anti-proliferative effect of EZH2 siRNA in RD cells.
RD cells treated with either CTR siRNA or EZH2 siRNA were cultured in
proliferating growth medium (GM, i.e., supplemented with 10% fetal calf
serum) for 3 days and then incubated with MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide, a tetrazole) reagent (Sigma Chemical
Co., St Louis, MO, USA), according to manufacturer’s recommendations.
*P<0.05 (Student’s t-test); Columns, means; Bars, SD. Results from three in-
dependent experiments are shown.
Additional file 3: Figure S2. Differentiation medium (DM, i.e.,
supplemented with 2% horse serum) does not potentiate EZH2
depletion-dependent myogenic-like differentiation of embryonal RD cells
compared to proliferating growth medium (GM, i.e., supplemented with
10% fetal calf serum). RD cells were transfected (t0) either with EZH2
siRNA or control (CTR) siRNA or with an EZH2 siRNA targeting the 5′UTR
of the endogenous EZH2 (EZH2 siRNA*) or the corresponding control
siRNA (CTR siRNA*) and after 24 h silenced again. Cells were cultured in
either GM or DM and media were replenished every two days. (a) West-
ern blot showing EZH2 and Myogenin in RD cells 72 h after EZH2 siRNA
or CTR siRNA transfection and in untreated RD cells. Representative of
two independent experiments. GAPDH served as loading control.
(b, left panels) Western blot showing EZH2 and H3K27me3 levels in RD
cells silenced with EZH2 siRNA* or CTR siRNA* 72 h after siRNA transfection.
(b, right panels) Western blot showing EZH2 and Myogenin in RD cells
72 h after EZH2 siRNA* or CTR siRNA* transfection and in untreated cells.
Representative of two independent experiments. GAPDH served as loading
control. (c, d) RD cells were silenced for EZH2 and analyzed for the induction
of muscle-like differentiation 5 days post-siRNA transfection. Media were
replenished every 2 days. Representative immunofluorescence showing
de novo expression of endogenous Myosin Heavy Chain (MHC, green;
Alexa Fluor 488 secondary antibody, #A11017: Invitrogen, Carlsbad,
CA) in multinucleated fibers of EZH2-depleted cells using (c) EZH2
siRNA and (d) an EZH2 siRNA targeting the 5′UTR of the endogenousEZH2 (EZH2 siRNA*) and their corresponding control siRNAs . DAPI
(blue) was used for nuclear staining. Representative of two assays.
Additional file 4: Figure S3. Effects of EZH2 depletion by short-hairpin
(shRNA) expression in RD cells cultured in proliferating growth medium
(GM, i.e., supplemented with 10% fetal calf serum). RD cells were infected
with lentiviral vectors expressing either a shRNA against EZH2 (EZH2
shRNA) or a non-targeting control shRNA (CTR shRNA). (a, left) mRNA
levels (real time qRT-PCR) of EZH2, Myogenin and MCK in EZH2 shRNA RD
cells both 4 days post-infection and after 30 days of selection in puromycin
(stably shRNA-expressing cells). Values were normalized to GAPDH levels and
expressed as fold increase over CTR shRNA (1 arbitrary unit, not reported).
Columns, means; Bars, SD. Results from two independent experiments are
shown. (a, right) Western blot showing levels of EZH2 in stably expressing
EZH2 and CTR shRNA RD cells. α-tubulin served as loading control.
Representative of two independent experiments. (b) Stably EZH2 and
CTR shRNA-expressing RD cells were analyzed for their myogeinc potential.
Representative immunofluorescence showing de novo expression of
endogenous Myosin Heavy Chain (MHC, red) in multinucleated fibers
of EZH2 shRNA-expressing cells after 6 days in culture. Representative
of two assays.
Additional file 5: Figure S4. Inhibiting EZH2 in RD cells by using the
catalytic inhibitor MC1948. (a) RD cells were treated with 5 μM MC1948 or
DMSO (vehicle) in proliferating growth medium (GM, i.e. supplemented
with 10% of fetal calf serum), harvested and counted at the indicated time
points starting at 24 h (day 1) from the onset of treatment. *P<0.05
(Student’s t-test); Bars, Standard Deviation (SD). (b) Western blot showing
levels of histone H3 trimethylation on Lys27 (H3K27me3) and EZH2 after
5 μM MC1948 treatment RD cells. Total Histone3 (H3) and α-tubulin served
as loading controls. Representative of 3 independent experiments. (c) RD
cells were analyzed for the induction of muscle-like differentiation by
immunofluorescence for Myosin Heavy Chain (MHC) protein after 6 days of
5 μM MC1948 treatment. Control cells treated with DMSO (vehicle) are
shown. Representative immunofluorescence of three assays.
Additional file 6: Figure S5. Differentiation medium (DM, i.e.,
supplemented with 2% horse serum) does not potentiate myogenic-like
differentiation of embryonal RD cells upon pharmacologic inhibition of
EZH2 compared to proliferating growth medium (GM, i.e., supplemented
with 10% fetal calf serum). Representative phase-contrast images of RD
cells analyzed for the induction of skeletal muscle-like phenotype after 4
days of either DZNep or MC1945 (5 μM both) treatment in GM or DM.
White arrows indicate multinucleated fibers. Control cells treated with
vehicle (i.e., water (UN) or DMSO) are shown. Magnification 200×.
Representative of two assays.
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